
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

**FORM S-1
REGISTRATION STATEMENT**
*UNDER
THE SECURITIES ACT OF 1933*

Treace Medical Concepts, Inc.
(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

3841
(Primary Standard Industrial
Classification Code Number)

47-1052611
(I.R.S. Employer
Identification Number)

**203 Fort Wade Rd., Suite 150
Ponte Vedra, Florida 32081
(904) 373-5940**
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

John T. Treace
Chief Executive Officer
**203 Fort Wade Rd., Suite 150
Ponte Vedra, Florida 32081
(904) 373-5940**
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Brian J. Cuneo
Phillip S. Stoup
Latham & Watkins LLP
140 Scott Drive
Menlo Park, California 94025
(650) 328-4600

Copies to:
Jaime A. Frias
Chief Legal & Compliance Officer
203 Fort Wade Rd., Suite 150
Ponte Vedra, Florida 32081
(904) 373-5940

Charles S. Kim
Dave Peinsipp
Kristin VanderPas
Denny Won
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. (File No. 333-254863)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.

CALCULATION OF REGISTRATION FEE

| Title of each class of securities to be registered | Amount to be registered(1) | Proposed maximum offering price per share | Proposed maximum aggregate offering price | Amount of registration fee(2) |
|--|----------------------------|---|---|-------------------------------|
| Common Stock, \$0.0001 par value per share | 2,156,250 | \$17.00 | \$36,656,250 | \$4,000 |

- (1) Represents only the additional number of shares being registered and includes 281,250 additional shares that the underwriters have the option to purchase. In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, the amount being registered does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1, as amended (File No. 333-254863).
- (2) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The Registrant previously registered securities at an aggregate offering price not to exceed \$17.00 on a Registration Statement on Form S-1, as amended (File No. 333-254863), which was declared effective by the Securities and Exchange Commission on April 22, 2021. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of \$36,656,250 is hereby registered.

This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

This registration statement is being filed with respect to the registration of 2,156,250 additional shares of common stock, par value \$0.001 per share, 281,250 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares, of Treace Medical Concepts, Inc., a Delaware corporation, pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended. The contents of the earlier registration statement on [Form S-1](#), as amended (File No. 333-254863) (the "Prior Registration Statement"), which was declared effective by the Securities and Exchange Commission on April 22, 2021, are incorporated in this registration statement by reference. This registration statement is being filed solely to increase the amount of securities offered pursuant to the Prior Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

Exhibit Index

| <u>Exhibit No.</u> | <u>Description</u> |
|--------------------|--|
| 5.1 | Opinion of Latham & Watkins LLP. |
| 23.1 | Consent of Independent Registered Public Accounting Firm. |
| 23.2 | Consent of Latham & Watkins LLP (included in Exhibit 5.1). |
| 24.1(1) | Power of Attorney. |

(1) Previously filed on the signature page to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-254863), originally filed with the Securities and Exchange Commission on March 30, 2021 and incorporated by reference herein.

Signatures

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ponte Vedra, State of Florida, on April 22, 2021.

Eargo, Inc.

By: /s/ John T. Treace

John T. Treace
Chief Executive Officer, Founder and Director

Power of Attorney

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

| <u>Signature</u> | <u>Title</u> | <u>Date</u> |
|---|---|----------------|
| <u>/s/ John T. Treace</u> John T. Treace | Chief Executive Officer, Founder and Director (<i>Principal Executive Officer</i>) | April 22, 2021 |
| <u>/s/ Mark L. Hair</u> Mark L. Hair | Chief Financial Officer (<i>Principal Financial and Principal Accounting Officer</i>) | April 22, 2021 |
| <u>*</u> James T. Treace | Chairman of the Board of Directors | April 22, 2021 |
| <u>*</u> John K. Bakewell | Director | April 22, 2021 |
| <u>*</u> F. Barry Bays | Director | April 22, 2021 |
| <u>*</u> Lawrence W. Hamilton | Director | April 22, 2021 |
| <u>*</u> Richard W. Mott | Director | April 22, 2021 |
| <u>*</u> Thomas W. Timbie | Director | April 22, 2021 |
| <u>*</u> John R. Treace | Director | April 22, 2021 |

*By: /s/ John T. Treace

John T. Treace
Attorney-in-Fact

140 Scott Drive
 Menlo Park, California 94025
 Tel: +1.650.328.4600 Fax: +1.650.463.2600
 www.lw.com

LATHAM & WATKINS LLP

FIRM / AFFILIATE OFFICES

| | |
|--------------|------------------|
| Beijing | Moscow |
| Boston | Munich |
| Brussels | New York |
| Century City | Orange County |
| Chicago | Paris |
| Dubai | Riyadh |
| Düsseldorf | San Diego |
| Frankfurt | San Francisco |
| Hamburg | Seoul |
| Hong Kong | Shanghai |
| Houston | Silicon Valley |
| London | Singapore |
| Los Angeles | Tokyo |
| Madrid | Washington, D.C. |
| Milan | |

April 22, 2021

Treace Medical Concepts, Inc.
 203 Fort Wade Rd., Suite 150
 Ponte Vedra, Florida 32081

Re: Form S-1 Registration Statement File No. 333-254863 and Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended

Ladies and Gentlemen:

We have acted as special counsel to Treace Medical Concepts, Inc., a Delaware corporation (the "**Company**"), in connection with the registration of shares of the Company's common stock, \$0.001 par value per share ("**Common Stock**"), pursuant to a registration statement on Form S-1 under the Securities Act of 1933, as amended (the "**Act**"), filed with the Securities and Exchange Commission (the "**Commission**") on March 30, 2021 (Registration No. 333-254863) (as amended, the "**Initial Registration Statement**") and a registration statement relating to the Initial Registration Statement filed pursuant to Rule 462(b) promulgated under the Act (the "**Post-Effective Amendment**" and together with the Initial Registration Statement, the "**Registration Statement**"). The Post-Effective Amendment relates to the registration of 2,156,250 shares of Common Stock of the Company (the "**Additional Shares**"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus (the "**Prospectus**"), other than as expressly stated herein with respect to the issue of the Additional Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the "**DGCL**"), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Additional Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in the circumstances contemplated by the form

LATHAM & WATKINS LLP

of underwriting agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Additional Shares will have been duly authorized by all necessary corporate action of the Company, and the Additional Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under the heading "Legal Matters." In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Latham & Watkins LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated April 16, 2021, with respect to the financial statements of Treace Medical Concepts, Inc. contained in the Registration Statement on Form S-1 (File No. 333-254863) which is incorporated by reference in this Registration Statement on Form S-1MEF. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and to the use of our name as it appears under the caption "Experts" in the prospectus incorporated by reference in this Registration statement.

/s/ GRANT THORNTON LLP

Jacksonville, Florida
April 22, 2021